Elivaldogene autotemcel

DB16746ApprovedGene Therapies

Elivaldogene autotemcel is a gene replacement therapy for treating early cerebral adrenoleukodystrophy comprising autologous hematopoietic stem cells transduced with a viral vector encoding ABCD1 complementary DNA for human adrenoleukodystrophy protein. It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy, an X-linked genetic disorder characterized by missing or non-functional ABCD1 gene that codes for ALDP.

Mechanism
Curator reviewed · 4 references
Primary indication
Elivaldogene autotemcel is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD).Curator reviewed · 1 structured indication
First approval
United States, 2022
Also known as
eli-cel
Brand names
  • Skysona

Resolves to

What you can answer from here — as of December 06, 2025

27Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 3 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Elivaldogene autotemcel, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account